What is the clinical significance of first-pass metabolism?

• A. The liver metabolizes drugs on their first pass after oral administration, reducing bioavailability; some drugs require non-oral routes.
• B. First-pass metabolism increases oral bioavailability for most drugs.
• C. Only intravenous drugs undergo first-pass metabolism.
• D. It is a theoretical concept with no clinical impact.

Answer: (A)

Oral drugs can be largely inactivated by the liver before they reach the systemic circulation, a process known as hepatic first-pass metabolism. After absorption from the gut, the drug travels via the portal vein to the liver, where metabolic enzymes (such as those in the cytochrome P450 system) can substantially reduce the amount that enters general circulation. This lowers the drug’s bioavailability, meaning a smaller fraction of the oral dose actually has systemic effect.

Clinically, this is why some drugs must be given by non-oral routes or at higher oral doses to achieve therapeutic levels. Routes that bypass first-pass metabolism—such as sublingual, rectal (to some extent), transdermal, inhalation, or intravenous administration—are used for drugs with extensive hepatic extraction. Factors like liver function, concurrent medications that inhibit or induce hepatic enzymes, and individual genetic differences can alter the extent of first-pass metabolism, contributing to variability in drug response. For example, drugs with strong first-pass effects may have low oral bioavailability and rely on alternative administration routes to be effective.

This concept is not about increasing bioavailability with first-pass, nor is it limited to intravenous drugs, and it clearly has real clinical implications.